Merck Acquiring Cladribine as Potential Generalized MG Treatment

Merck Acquiring Cladribine as Potential Generalized MG Treatment

315046

Merck Acquiring Cladribine as Potential Generalized MG Treatment

Merck KGaA has acquired Chord Therapeutics and the rights to continue developing CRD1 (cladribine), Chord’s lead candidate for treatment of generalized myasthenia gravis. “I am particularly pleased that Chord’s focus on severe, rare neurological conditions will be complemented by Merck’s established leadership with cladribine,” Arthur Roach, founder and director of Chord Therapeutics, said in a press release. Merck KGaA, known as EMD Serono in North America, markets Mavenclad, a short-course oral tablet form of cladribine approved…

You must be logged in to read/download the full post.